Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast Cancer: Preliminary results from BOLERO-2

Hortobagyi, GN and Piccart-Gebhart, MJ and Rugo, HS and Burris, HA and Campone, M and Noguchi, S and Perez, AT and Deleu, I and Shtivelband, M and Provencher, L and Masuda, N and Dakhil, SR and Anderson, I and Chen, D and Damask, A and Huang, A and McDonald, R and Taran, T and Sahmoud, T and Baselga, J (2013) Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast Cancer: Preliminary results from BOLERO-2. Journal of Clinical Oncology.

Item Type: Article
Additional Information: NIBR author: institute: NIBR contributor address: Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA. Jules Bordet Canc Inst, Brussels, Belgium. Univ Calif San Francisco, San Francisco, CA 94143 USA. Sarah Cannon Res Inst, Nashville, TN USA. Ctr Rech Cancerol, CLCC Rene Gauducheau, St Herblain, France. Osaka Univ, Osaka, Japan. Mem Canc Inst, Breast Canc Program, Hollywood, FL USA. AZ Nikolaas, St Niklaas, Belgium. Ironwood Canc & Res Ctr, Chandler, AZ USA. Hop St Sacrement, Ctr Malad Sein Deschenes Fabia, Quebec City, PQ, Canada. Osaka Natl Hosp, Osaka, Japan. Canc Ctr Kansas, Wichita, KS USA. Redwood Reg Oncol Ctr, Santa Rosa, CA USA. Novartis Pharmaceut, Oncol, Florham Pk, NJ USA. Novartis Inst BioMed Res, Cambridge, MA USA. Novartis Inst BioMed Res Inc, Cambridge, MA USA. Novartis Pharmaceut, Florham Pk, NJ USA. Novartis Pharmaceut, E Hanover, NJ USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/23430

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.